If not the world’s leading gene therapy research center, Nationwide Children’s Hospital seeks to aggressively expand into gene therapy research with the launch of a $74 million biotechnology manufacturing facility for genetic material used in research and clinical trials.
According to local media reports, including NBC4i, Andelyn Biosciences Inc., a Nationwide Children’s Hospital affiliate, looks to be near selecting a physical site for the facility based on reports in the media that a project map in Columbus City Council evidences an 8-acre parcel within Ohio State University (OSU) west campus at the southwest corner of Lane Avenue and Carmack Road. NBC4i reports that OSU and the hospital have confirmed the project is in proposal status and not yet final.
Who is Andelyn Biosciences?
Andelyn Biosciences, a for-profit affiliate of Nationwide Children’s Hospital, was created to take on, manage, and grow in-house genetic material production inside the Wexner Research Institute, part of Nationwide Children’s Hospital. By late 2020, Andelyn Biosciences will establish its milestone of becoming a Phase 3 compliant Good Manufacturing Practices (cGMP) clinical manufacturing facility producing gene therapy and cell-based products. With a unique business model—being part of what is arguably the most elite gene therapy research center in the world (TrialSite News puts the University of PA in the same category)—leads to reinvestment into pioneering research conducted at the Abigail Wexner Research Institute on a broad range of health challenges facing affecting health.
The Abigail Wexner Research Institute
This is the center’s most recent name as of 2019. Priorly, it has been known as the Research Institute at Nationwide Children’s Hospital. The research center traces its roots back to 1892. It underwent considerable expansion post World War II. By 1998 the Children’s Hospital Research Foundation became the Columbus Children’s Research Institute. After a gift from the Nationwide Foundation in 2007, it became known the Research Institute at Nationwide Children’s Hospital.
The Columbus, Ohio-based team seeks to build an 85,000-square-foot facility adding exponential gene therapy-based manufacturing capacity for online, ready to roll production by 2023.
Call to Action: Interested in doing business with what is a formidable player in the gene therapy production space? Wade M. Macedone, Executive Director & General Manager of the Abigail Wexner Research Institute, leads the charge.